Victoria Chernyak, Milana Flusberg, Jesse Berman, Kate C. Fruitman, Mariya Kobi, Kathryn J. Fowler, Claude B. Sirlin – 25 July 2019 – The purpose of this study was to assess the concordance in categorization and radiologic T staging using Liver Imaging Reporting and Data System (LI‐RADS, LR) version 2017 (v2017), version 2018 (v2018), and the Organ Procurement and Transplantation Network (OPTN) criteria. All magnetic resonance imaging and computed tomography reports using a standardized LI‐RADS macro between April 2015 and March 2018 were identified retrospectively.

Alcoholic hepatitis has high short-term mortality with limited medical therapeutic options. Liver transplantation remains controversial for this indication given inability of these patients to meet six months of sobriety.

Michael C. Lawrence, Carly M. Darden, Srividya Vasu, Kenjiro Kumano, Jinghua Gu, Xuan Wang, Jinyan Chan, Zhaohui Xu, Benjamin F. Lemoine, Phuong Nguyen, Cynthia Smitherman, Bashoo Naziruddin, Giuliano Testa – 24 July 2019 – The human liver’s capacity to rapidly regenerate to a full‐sized functional organ after resection has allowed successful outcomes for living donor liver transplantation (LDLT) procedures. However, the ability to detect and track physiological changes occurring during liver regeneration after resection and throughout the restoration process is still lacking.

Ramesh Kumar – 24 July 2019

Management of HCV after therapy has complexity if patients continue to engage in high risk activities, are at risk for advanced liver disease progression or have failed first line therapy. In addition, these complexities are especially important to consider as HCV therapy moves outside of subspecialty care. We will utilize a live webinar format that will be recorded for on-demand viewing on Liver Learning ® .Stuart C. Gordon Dr. Gordon is a Professor of Medicine at Wayne State University School of Medicine and Director, Division of Hepatology, at Henry Ford Hospital.

23 July 2019

Xiaobo Wang, Mark R. Sommerfeld, Kerstin Jahn‐Hofmann, Bishuang Cai, Aveline Filliol, Helen E. Remotti, Robert F. Schwabe, Aimo Kannt, Ira Tabas – 23 July 2019 – Nonalcoholic steatohepatitis (NASH) is emerging as a major public health issue and is associated with significant liver‐related morbidity and mortality. At present, there are no approved drug therapies for NASH.

23 July 2019

23 July 2019

Michelle A. Camarata, Aftab Ala, Michael L. Schilsky – 23 July 2019 – We evaluate Wilson disease (WD) treatment with zinc acetate (U.S. Food and Drug Administration approved) and alternative zinc salts. Studies examining zinc therapy in WD are few, and data on alternative zinc salts are limited. We describe one of the largest recent studies of zinc therapy in WD.